By Maggie Fick and Jacob Gronholt-Pedersen LONDON/COPENHAGEN, Feb 4 (Reuters) - Danish obesity drug giant Novo Nordisk is set ...
During the first six months of Maziar Mike Doustdar's tenure as Novo Nordisk's CEO, the company enjoyed a run of positive ...
Novo Nordisk’s ‘There’s Only One Ozempic’ campaign is about reasserting the drugmaker’s brand name in an increasingly ...
Lawsuit claims Novo Nordisk delayed generic Victoza using patent tactics and settlements, preserving monopoly pricing and ...
Amid a viral social media trend glorifying the halcyon days of 2016, Novo Nordisk has gone back an extra decade to find ...
Novo Nordisk is considering additional regulatory filings for CagriSema – already submitted in the US for obesity – after the drug outperformed Ozempic in a head-to-head diabetes study.
Novo Nordisk is worried about competition and wants to be seen as the cool kid... by using a 20-year-old ad format.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results